DSM looking at options to exit its caprolactam business

14:51 PM | July 3, 2013 | Natasha Alperowicz

DSM today declined to comment on a Bloomberg report that it is considering exiting the caprolactam business. However, it confirmed previously announced plans to reduce its exposure to the merchant...